Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Enliven Therapeutics (ELVN) Equity Average (2019 - 2026)

Enliven Therapeutics has reported Equity Average over the past 8 years, most recently at $456.5 million for Q1 2026.

  • Quarterly results put Equity Average at $456.5 million for Q1 2026, up 52.63% from a year ago — trailing twelve months through Mar 2026 was $456.5 million (up 52.63% YoY), and the annual figure for FY2025 was $384.7 million, up 38.45%.
  • Equity Average reached $456.5 million in Q1 2026 per ELVN's latest filing, down from $467.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $482.3 million in Q3 2025 and bottomed at -$72.5 million in Q4 2022.
  • Median Equity Average over the past 5 years was $285.2 million (2023), compared with a mean of $233.1 million.
  • The largest annual shift saw Equity Average tumbled 356.56% in 2022 before it soared 621.77% in 2023.
  • Over 5 years, Equity Average stood at -$72.5 million in 2022, then soared by 450.29% to $253.8 million in 2023, then grew by 17.85% to $299.1 million in 2024, then surged by 56.41% to $467.9 million in 2025, then dropped by 2.43% to $456.5 million in 2026.
  • Business Quant data shows Equity Average for ELVN at $456.5 million in Q1 2026, $467.9 million in Q4 2025, and $482.3 million in Q3 2025.